Technical Analysis for BLRX - BioLineRx Ltd.

Grade Last Price % Change Price Change
grade C 2.15 12.57% 0.24
BLRX closed up 12.57 percent on Friday, August 7, 2020, on 82 percent of normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
Historical BLRX trend table...

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish 0.00%
Crossed Above 200 DMA Bullish 0.00%
Crossed Above 20 DMA Bullish 0.00%
Earnings Movers Other 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Fell Below 200 DMA Bearish 12.57%
Fell Below 20 DMA Bearish 12.57%
Slingshot Bullish Bullish Swing Setup 12.57%
Earnings Movers Other 12.57%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates. The company's development pipeline consists of six clinical-stage therapeutic candidates, including BL-1020, which is in Phase II/III clarity trial to enhance cognitive function in schizophrenia patients; BL-1040, a novel polymer solution that is under pivotal CE-Mark registration trial for use in the prevention of pathological cardiac remodeling following a myocardial infarction; and BL-5010, a medical device, which has completed Phase I/II clinical trials for the non-surgical removal of skin lesions. Its development pipeline also includes BL-1021 that is in Phase Ia clinical trial for the treatment of neuropathic pain, or pain that results from damage to nerve fibers; BL-7040, which is in Phase II clinical trial for the treatment of inflammatory bowel disease; and BL-8040, a peptide that has completed Phase I/II clinical trial for the treatment of acute myeloid leukemia and other hematological cancers. The company also has six products in various pre-clinical development stages for indications, such as central nervous system diseases, infectious diseases, cardiovascular, and autoimmune diseases. In addition, it operates a biotechnology incubator to evaluate therapeutic candidates. BioLineRx Ltd. has license agreements with Genoscience; Compugen Ltd.; RFS Pharma; Yissum and University of Genoa, Italy; Gestion Univalor, Limited Partnership; Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd.; and Ikaria. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
Biotechnology Health Pain Infectious Diseases Autoimmune Diseases Drug Discovery Pharmacology Clinical Trial Acute Myeloid Leukemia Schizophrenia Inflammatory Bowel Disease Design Of Experiments Clinical Research Treatment Of Acute Myeloid Leukemia Central Nervous System Diseases Hematological Cancers Biotechnology Companies Compugen Treatment Of Inflammatory Bowel Disease

Is BLRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 3.642
52 Week Low 1.06
Average Volume 702,360
200-Day Moving Average 2.02
50-Day Moving Average 1.86
20-Day Moving Average 2.03
10-Day Moving Average 2.17
Average True Range 0.18
ADX 31.38
+DI 25.22
-DI 17.81
Chandelier Exit (Long, 3 ATRs ) 2.02
Chandelier Exit (Short, 3 ATRs ) 2.24
Upper Bollinger Band 2.41
Lower Bollinger Band 1.65
Percent B (%b) 0.65
BandWidth 37.40
MACD Line 0.11
MACD Signal Line 0.11
MACD Histogram -0.0011
Fundamentals Value
Market Cap 205.58 Million
Num Shares 95.6 Million
EPS -0.28
Price-to-Earnings (P/E) Ratio -7.68
Price-to-Sales 0.00
Price-to-Book 1.78
PEG Ratio 0.18
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.54
Resistance 3 (R3) 2.50 2.34 2.48
Resistance 2 (R2) 2.34 2.24 2.36 2.45
Resistance 1 (R1) 2.24 2.18 2.29 2.28 2.43
Pivot Point 2.08 2.08 2.10 2.10 2.08
Support 1 (S1) 1.98 1.98 2.03 2.02 1.87
Support 2 (S2) 1.82 1.92 1.84 1.85
Support 3 (S3) 1.72 1.82 1.83
Support 4 (S4) 1.76